Spectral Medical Inc.

102 articles about Spectral Medical Inc.

• Spectral Medical Provides Tigris Trial Update - April 10, 2024

  4/10/2024

  Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Chair to Retire From the Board of Directors

  4/2/2024

  Spectral Medical Inc. announced that Anthony Bihl III, Spectral’s Chairman, will be retiring from the Board at Spectral’s upcoming Shareholder Meeting in June 2024.

• Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update97 patients enrolled

  3/28/2024

  Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

• Spectral Medical Provides February Tigris Trial Update

  2/28/2024

  Spectral Medical Inc. today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

  2/21/2024

  Spectral Medical Inc. is pleased to announce an extension to its supply and distribution agreement with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc., originally entered into in February 2020.

• Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

  2/15/2024

  Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

• Spectral Medical Provides Early February Tigris Trial Update

  2/5/2024

  Spectral Medical Inc today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Provides January Tigris Trial Update

  1/30/2024

  Spectral Medical Inc. today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

  1/10/2024

  Spectral Medical Inc. today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Provides November Tigris Trial Update

  12/4/2023

  Spectral Medical Inc. today provided an update for the month of November on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Announces CFO Departure

  12/1/2023

  Spectral Medical Inc. today announced that Blair McInnis has provided notice of his resignation as Chief Financial Officer of the Company, which is effective immediately, to pursue a new opportunity.

• Spectral Medical Announces Publication of Tigris Trial Methods Paper and Simulation of Results

  11/14/2023

  Spectral Medical Inc. announced the publication of its Tigris trial methods paper in Critical Care, which discusses the use of Bayesian methods in clinical trial design.

• Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic

  10/16/2023

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as its 19th clinical site for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults being treated for endotoxemia and septic shock.

• Spectral Medical Provides Tigris Trial Update

  10/3/2023

  Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an update on the progress of its Tigris trial including patient enrollment and new trial site additions to further accelerate patient enrollment.

• Spectral Medical Supports World Sepsis DayWorld Sepsis Day is Today, September 13, 2023

  9/13/2023

  Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to support World Sepsis Day today. World Sepsis Day is an initiative by the Global Sepsis Alliance and was established in 2012.

• Spectral Medical Announces Second Quarter Results and Provides Corporate UpdateTigris Trial Enrollment Reaches 71 Patients

  8/10/2023

  Spectral Medical Inc. today announced its financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Spectral Medical Announces Tigris Clinical Trial Update

  7/25/2023

  Spectral Medical Inc. today announced that it has enrolled a total of 69 patients for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Announces the Opening of Three Additional Tigris Clinical Trial Sites

  7/5/2023

  Spectral Medical Inc. announced the opening of three new clinical trials sites, the University of Alabama at Birmingham, Rutgers, The State University of New Jersey, and a major medical center in Wisconsin, bringing the total number of active clinical trial sites to eighteen for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

• Spectral Medical Appoints Former FDA Director, Dr. David W. Feigal, Jr., to Its Board of Directors

  6/27/2023

  Spectral Medical Inc. today announced that it has appointed Dr. David W. Feigal, Jr., M.D., M.P.H., to its Board of Directors.

• Spectral Medical Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

  6/20/2023

  Spectral Medical Inc., a late stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an enrollment update on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.